CD56+ hematological neoplasms presenting in the skin: A retrospective analysis of 23 new cases and 130 cases from the literature

Annals of Oncology

Volumn 15, Issue 7, 2004, Pages 1097-1108

  Bekkenk, M W ^a   Jansen, P M ^a   Meijer, C J L M ^b   Willemze, R ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

CD56; Classification; Cutaneous; Leukemia; NK T cell lymphoma; Prognosis; Treatment

Indexed keywords

BLEOMYCIN; CD56 ANTIGEN; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; METHOTREXATE; PREDNISONE; TENIPOSIDE; VINCRISTINE;

ADULT; AGED; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL FEATURE; CLINICAL PROTOCOL; CONTROLLED STUDY; DISEASE ACTIVITY; FEMALE; FOLLOW UP; HISTOLOGY; HUMAN; IMMUNOPHENOTYPING; LEUKEMIA; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL LITERATURE; MYELOID LEUKEMIA; NOSE CARCINOMA; PANNICULITIS; PERIPHERAL T CELL LYMPHOMA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SKIN LYMPHOMA; T CELL LYMPHOMA; TUMOR DIFFERENTIATION; TUMOR LOCALIZATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD30; ANTIGENS, CD56; FEMALE; FOLLOW-UP STUDIES; HEMATOLOGIC NEOPLASMS; HUMANS; KILLER CELLS, NATURAL; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SKIN; SURVIVAL ANALYSIS; T-LYMPHOCYTES;

EID: 4143108007     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdh268     Document Type: Article

References (72)

1. Griffin JD, Hercend T, Beveridge R et al. Characterization of an antigen expressed by human natural killer cells. J Immunol 1983; 130: 2947-2951.
2. Jaffe ES, Harris NL, Stein H, Vardiman JW (eds): World Health Organization classification of tumours. Pathology and Genetics of Tumours of the Hematopoetic and Lymphoid Tissues. Lyon, France: IARC Press 2001.
3. Petrella T, Comeau MR, Maynadie M et al. 'Agranular CD4+ CD56+ hematodermic neoplasm' (blastic NK-cell lymphoma) originates from a population of CD56+ precursor cells related to plasmacytoid monocytes. Am J Surg Pathol 2002; 26: 852-862.
4. Petrella T, Dalac S, Mayandie M et al. CD4+ CD56+ cutaneous neoplasms: a distinct hematologic entity? Groupe Francais d'Etude des Lymphomes Cutanes (GFELC). Am J Surg Pathol 1999; 23: 137-146.
5. Reimer P, Rüdiger T, Kraemer D et al. What is CD4+ CD56+ malignancy and how should it be treated? Bone Marrow Transplantation 2003; 32: 637-646.
6. Willemze R, Kerl H, Sterry W et al. EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood 1997; 90: 354-371.
7. Abe Y, Muta K, Ohshima K et al. Subcutaneous panniculitis by Epstein-Barr virus-infected natural killer (NK) cell proliferation terminating in aggressive subcutaneous NK cell lymphoma. Am J Hematol 2000; 64: 221-225.
8. Ahn SJ, Jang KA, Choi JH et al. Nasal and nasal type CD56+natural killer cell/T-cell lymphoma: a case with rapid progression to bone marrow involvement. Br J Dermatol 2000; 142: 1021-1025.
9. Bayerl MG, Rakozy CK, Mohamed AN et al. Blastic natural killer cell lymphoma/leukemia: a report of seven cases. Am J Clin Pathol 2002; 117: 41-50.
10. Bekkenk MW, Kluin PM, Jansen PM et al. Lymphomatoid papulosis with a natural killer-cell phenotype. Br J Dermatol 2001; 145: 318-322.
11. Chan JK, Sin VC, Wong KF et al. Nonnasal lymphoma expressing the natural killer cell marker CD56: a clinicopathologic study of 49 cases of an uncommon aggressive neoplasm. Blood 1997; 89: 4501-4513.
12. Chan JK, Tsang WY, Lau WH et al. Aggressive T/natural killer cell lymphoma presenting as testicular tumor. Cancer 1996; 77: 1198-1205.
13. Chang SE, Choi HJ, Huh J et al. A case of primary cutaneous CD56+ TdT+, CD4+, blastic NK-cell lymphoma in a 19-year-old woman. Am J Dermatopathol 2002; 24: 72-75.
14. Chang SE, Choi JH, Sung KJ et al. Cutaneous nasal-type CD56+ natural killer/T-cell lymphoma preceded by Epstein-Barr virus antigenaemia. Br J Dermatol 2001; 145: 668-669.
15. Chang SE, Huh J, Choi JH et al. Clinicopathological features of CD56+ nasal-type T/natural killer cell lymphomas with lobular panniculitis. Br J Dermatol 2000; 142: 924-930.
16. Chang SE, Park IJ, Huh J et al. CD56 expression in a case of primary cutaneous CD30+ anaplastic large cell lymphoma. Br J Dermatol 2000; 142: 766-770.
17. Chang SE, Yoon GS, Huh J et al. Comparison of primary and secondary cutaneous CD56+NK/T cell lymphomas. Appl Immunohistochem Mol Morphol 2002; 10: 163-170.
18. Coupland SE, Foss HD, Assaf C et al. T-cell and T/natural killer-cell lymphomas involving ocular and ocular adnexal tissues: a clinicopathologic, immunohistochemical, and molecular study of seven cases. Ophthalmology 1999; 106: 2109-2120.
19. Dummer R, Potoczna N, Haffner AC et al. A primary cutaneous non-T, non-B CD4+, CD56+ lymphoma. Arch Dermatol 1996; 132: 550-553.
20. Falcao RP, Garcia AB, Marques MG et al. Blastic CD4 NK cell leukemia/lymphoma: a distinct clinical entity. Leuk Res 2002; 26: 803-807.
21. Feuillard J, Jacob MC, Valensi F et al. Clinical and biologic features of CD4(+)CD56(+) malignancies. Blood 2002; 99: 1556-1563.
22. Ginarte M, Abalde MT, Peteiro C et al. cell leukemia/lymphoma with cutaneous involvement. Dermatology 2000; 201: 268-271.
23. Gould JW, Eppes RB, Gilliam AC et al. Solitary primary cutaneous CD30+ large cell lymphoma of natural killer cell phenotype bearing the t(2;5)(p23;q35) translocation and presenting in a child. Am J Dermatopathol 2000; 22: 422-428.
24. Hirakawa S, Kuyama M, Takahashi S et al. Nasal and nasal-type natural killer/T-cell lymphoma. J Am Acad Dermatol 1999; 40: 268-272.
25. Jang KA, Choi JH, Sung KJ et al. Primary CD56+ nasal-type T/natural killer-cell subcutaneous panniculitic lymphoma: presentation as haemophagocytic syndrome. Br J Dermatol 1999; 141: 706-709.
26. Kamarashev J, Burg G, Mingari MC et al. Differential expression of cytotoxic molecules and killer cell inhibitory receptors in CD8+ and CD56+ cutaneous lymphomas. Am J Pathol 2001; 158: 1593-1598.
27. Kameoka J, Ichinohasama R, Tanaka M et al. A cutaneous agranular CD2-CD4+ CD56+ lymphoma: report of two cases and review of the literature. Am J Clin Pathol 1998; 110: 478-488.
28. Kanavaros P, Lescs MC, Briere J et al. Nasal T-cell lymphoma: a clinicopathologic entity associated with peculiar phenotype and with Epstein-Barr virus. Blood 1993; 81: 2688-2695.
29. Kato N, Yasukawa K, Kimura K et al. CD2- CD4+ CD56+ hematodermic/hematolymphoid malignancy. J Am Acad Dermatol 2001; 44: 231-238.
30. Kato N, Yasukawa K, Onozuka T et al. Nasal and nasal-type T/NK-cell lymphoma with cutaneous involvement. J Am Acad Dermatol 1999; 40: 850-856.
31. Khoury JD, Medeiros LJ, Manning JT et al. CD56(+) TdT(+) blastic natural killer cell tumor of the skin: a primitive systemic malignancy related to myelomonocytic leukemia. Cancer 2002; 94: 2401-2408.
32. Kimura S, Kakazu N, Kuroda J et al. Agranular CD4+ CD56+ blastic natural killer leukemia/lymphoma. Ann Hematol 2001; 80: 228-231.
33. Knudsen H, Gronbaek K, thor Straten P et al. A case of lymphoblastoid natural killer (NK)-cell lymphoma: association with the NK-cell receptor complex CD94/NKG2 and TP53 intragenic deletion. Br J Dermatol 2002; 146: 148-153.
34. Ko YH, Ree HJ, Kim WS et al. Clinicopathologic and genotypic study of extranodal nasal-type natural killer/T-cell lymphoma and natural killer precursor lymphoma among Koreans. Cancer 2000; 89: 2106-2116.
35. Kojima H, Mukai HY, Shinagawa A et al. Clinicopathological analyses of 5 Japanese patients with CD56+ primary cutaneous lymphomas. Int J Hematol 2000; 72: 477-483.
36. Kwong YL, Chan AC, Liang RH. Natural killer cell lymphoma/leukemia: pathology and treatment. Hematol Oncol 1997; 15: 71-79.
37. Ling TC, Harris M, Craven NM. Epstein-Barr virus-positive blastoid nasal T/natural killer-cell lymphoma in a Caucasian. Br J Dermatol 2002; 146: 700-703.
38. Lima M, Goncalves C, Teixeira MA et al. Aggressive natural-killer cell lymphoma presenting with skin lesions, breast nodule, suprarenal masses and life-threatening pericardial and pleural effusions. Leuk Lymphoma 2001; 42: 1385-1391.
39. Marzano AV, Berti E, Paulli M et al. Cytophagic histiocytic panniculitis and subcutaneous panniculitis-like T-cell lymphoma: report of 7 cases. Arch Dermatol 2000; 136: 889-896.
40. Matano S, Nakamura S, Nakamura S et al. Monomorphic agranular natural killer cell lymphoma/leukemia with no Epstein-Barr virus association. Acta Haematol 1999; 101: 206-208.
41. Mraz-Gernhard S, Natkunam Y, Hoppe RT et al. Natural killer/natural killer-like T-cell lymphoma, CD56+, presenting in the skin: an increasingly recognized entity with an aggressive course. J Clin Oncol 2001; 19: 2179-2188.
42. Mukai HY, Kojima H, Suzukawa K et al. High-dose chemotherapy with peripheral blood stem cell rescue in blastoid natural killer cell lymphoma. Leuk Lymphoma 1999; 32: 583-588.
43. Murakami Y, Nagae S, Matsuishi E et al. A case of CD56+ cutaneous aleukaemic granulocytic sarcoma with myelodysplastic syndrome. Br J Dermatol 2000; 143: 587-590.
44. Nakamura S, Suchi T, Koshikawa T et al. Clinicopathologic study of CD56 (NCAM)-positive angiocentric lymphoma occurring in sites other than the upper and lower respiratory tract. Am J Surg Pathol 1995; 19: 284-296.
45. Natkunam Y, Smoller BR, Zehnder JL et al. Aggressive cutaneous NK and NK-like T-cell lymphomas: clinicopathologic, immunohistochemical, and molecular analyses of 12 cases. Am J Surg Pathol 1999; 23: 571-581.
46. Natkunam Y, Warnke RA, Haghighi B et al. Co-expression of CD56 and CD30 in lymphomas with primary presentation in the skin: clinicopathologic, immunohistochemical and molecular analyses of seven cases. J Cutan Pathol 2000; 27: 392-399.
47. Noguchi M, Kawano Y, Sato N et al. T-cell lymphoma of CD3+ CD4+ CD56+ granular lymphocytes with hemophagocytic syndrome. Leuk Lymphoma 1997; 26: 349-358.
48. Paulli M, Boveri E, Rosso R et al. CD56/neural cell adhesion molecule expression in primary extranodal Ki-1/CD30+ lymphoma. Report of a pediatric case with simultaneous cutaneous and bone localizations. Am J Dermatopathol 1997; 19: 384-390.
49. Radonich MA, Lazova R, Bolognia J. Cutaneous natural killer/T-cell lymphoma. J Am Acad Dermatol 2002; 46: 451-456.
50. Rakozy CK, Mohamed AN, Vo TD et al. CD56+/CD4+ lymphomas and leukemias are morphologically, immunophenotypically, cytogenetically, and clinically diverse. Am J Clin Pathol 2001; 116: 168-176.
51. Salhany KE, Macon WR, Choi JK et al. Subcutaneous panniculitis-like T-cell lymphoma: clinicopathologic, immunophenotypic, and genotypic analysis of alpha/beta and gamma/delta subtypes. Am J Surg Pathol 1998; 22: 881-893.
52. Sanda T, Lida S, Ito M et al. Successful treatment of nasal T-cell lymphoma with a combination of local irradiation and high-dose chemotherapy. Int J Hematol 2002; 75: 195-200.
53. Savoia P, Fierro MT, Novelli M et al. CD56-positive cutaneous lymphoma: a poorly recognized entity in the spectrum of primary cutaneous disease. Br J Dermatol 1997; 137: 966-971.
54. Siu LL, Chan JK, Kwong YL. Natural killer cell malignancies: clinicopathologic and molecular features. Histol Histopathol 2002; 17: 539-554.
55. Takahashi N, Miura I, Chubachi A et al. A clinicopathological study of 20 patients with T/natural killer (NK)-cell lymphoma-associated hemophagocytic syndrome with special reference to nasal and nasal-type NK/T-cell lymphoma. Int J Hematol 2001; 74: 303-308.
56. Takeshita M, Akamatsu M, Ohshima K et al. Angiocentric immunoproliferative lesions of the skin show lobular panniculitis and are mainly disorders of large granular lymphocytes. Hum Pathol 1995; 26: 1321-1328.
57. Tao J, Shelat SG, Jaffe ES et al. Aggressive Epstein-Barr virus-associated, CD8+, CD30+, CD56+, surface CD3-, natural killer (NK)-like cytotoxic T-cell lymphoma. Am J Surg Pathol 2002; 26: 111-118.
58. Uchiyama N, Ito K, Kawai K et al. CD2-, CD4+, CD56+ agranular natural killer cell lymphoma of the skin. Am J Dermatopathol 1998; 20: 513-517.
59. Yamashita Y, Tsuzuki T, Nakayama A et al. A case of natural killer/T cell lymphoma of the subcutis resembling subcutaneous panniculitis-like T cell lymphoma. Pathol Int 1999; 49: 241-246.
60. Yamazaki M, Kakuta M, Takimoto R et al. Nasal natural killer cell lymphoma presenting as lethal midline granuloma. Int J Dermatol 2000; 39: 931-934.
61. Yamada O, Ichikawa M, Okamota T et al. Killer T-cell induction in patients with blastic natural killer cell lymphoma/leukemia: implications for successful treatment and possible therapeutic strategies. Br J Haematol 2001; 113: 153-160.
62. Amo Y, Ogata F, Yonemoto K et al. CD56-positive cutaneous lymphoma with multicentric Castleman's disease-like systemic manifestations. J Dermatol 2001; 28: 746-752.
63. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 157-181.
64. Herling M, Teitell MA, Shen RR et al. TCL1 expression in plasmacytoid dendritic cells (DC2s) and the related CD4+ CD56+ blastic tumors of skin. Blood 2003; 101: 5007-5009.
65. Munoz L, Nomdedeu JF, Lopez O et al. Interleukine-3 receptor alpha chain (CD123) is widely expressed in hematologic malignancies. Haematologica 2001; 86: 1261-1269.
66. Chaperot L, Bendriss N, Maches O et al. Identification of a leukemic counterpart of the plasmacytoid dendritic cells. Blood 2001; 97: 3210-3217.
67. Berti E, Tomasini D, Vermeer MH et al. Primary cutaneous CD8-positive epidermotropic cytotoxic T cell lymphomas. A distinct clinicopathological entity with an aggressive clinical behavior. Am J Pathol 1999; 155: 483-492.
68. Wechsler J, Willemze R, van der Brule A et al. Differences in Epstein-Barr virus expression between primary and secondary cutaneous angiocentric lymphomas. French Study Group of Cutaneous Lymphomas. Arch Dermatol 1998; 134: 479-484.
69. Santucci M, Pimpinelli N, Massi D et al. Cytotoxic/natural killer cell cutaneous lymphomas. Report of EORTC Cutaneous Lymphoma Task Force Workshop. Cancer 2003; 97: 610-627.
70. Hoque SR, Child FJ, Whittaker SJ et al. Subcutaneous panniculitis-like T-cell lymphoma: a clinicopathological, immunophenotypic and molecular analysis of six patients. Br J Dermatol 2003; 148: 516-525.
71. Suzuki R, Kagami Y, Takeuchi K et al. Prognostic significance of CD56 expression for ALK-positive and ALK-negative anaplastic large cell lymphoma of T/null cell phenotype. Blood 2000; 96: 2993-3000.
72. Bekkenk MW, Geelen FA, van Voorst Vader PC et al. Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood 2000; 95: 3653-3661.